PubRank

Dennis J Selkoe

Author PubWeight™ 329.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 49.51
2 Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002 19.36
3 Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007 17.69
4 Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008 17.09
5 Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2004 9.73
6 A beta oligomers - a decade of discovery. J Neurochem 2007 8.88
7 Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007 8.27
8 Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009 7.02
9 Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003 5.44
10 α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011 5.27
11 Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004 4.88
12 Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci 2006 4.14
13 Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003 4.11
14 Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006 3.74
15 Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005 3.43
16 Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A 2003 3.36
17 Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005 3.28
18 Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 2004 3.24
19 Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011 3.11
20 Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 2010 2.77
21 Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012 2.77
22 Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008 2.77
23 Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 2005 2.57
24 Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004 2.50
25 A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci 2007 2.48
26 Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology 2013 2.47
27 The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003 2.43
28 Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 2009 2.38
29 Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011 2.33
30 The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010 2.29
31 The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem 2003 2.22
32 Purification and characterization of the human gamma-secretase complex. Biochemistry 2004 2.18
33 Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004 2.16
34 Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A 2002 2.16
35 Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012 2.01
36 Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem 2008 2.00
37 Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007 1.95
38 The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J Neurochem 2011 1.93
39 Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem 2003 1.83
40 Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 2007 1.81
41 Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev 2008 1.79
42 Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A 2006 1.77
43 Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum Mol Genet 2007 1.76
44 Environmental novelty activates β2-adrenergic signaling to prevent the impairment of hippocampal LTP by Aβ oligomers. Neuron 2013 1.76
45 Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol 2008 1.75
46 Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004 1.66
47 Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry 2004 1.61
48 Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003 1.59
49 Inflammation and therapeutic vaccination in CNS diseases. Nature 2002 1.58
50 Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med 2007 1.55
51 Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002 1.54
52 Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci 2011 1.53
53 Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One 2009 1.52
54 Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 2002 1.52
55 Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J Biol Chem 2004 1.49
56 Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 2006 1.48
57 Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol 2008 1.45
58 gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem 2005 1.45
59 A seed for Alzheimer amyloid in the brain. J Neurosci 2004 1.45
60 A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 2009 1.44
61 Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005 1.44
62 Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J 2004 1.43
63 Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s). Biochemistry 2003 1.42
64 Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 2011 1.42
65 Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J Biol Chem 2003 1.42
66 Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 2012 1.37
67 Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis 2009 1.37
68 Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 2007 1.36
69 Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One 2010 1.35
70 Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci 2005 1.34
71 Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 2003 1.32
72 Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 2008 1.30
73 Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development. J Neurosci 2010 1.29
74 Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 2005 1.26
75 Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis 2008 1.23
76 Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J Biol Chem 2003 1.22
77 gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. Biochemistry 2003 1.22
78 Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem 2007 1.22
79 New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement 2013 1.22
80 Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci 2004 1.19
81 Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 2011 1.17
82 LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis 2008 1.15
83 Alzheimer disease in 2020. Cold Spring Harb Perspect Med 2012 1.15
84 Aβ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging 2010 1.14
85 Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 2007 1.13
86 Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol Dis 2003 1.11
87 Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiol Dis 2005 1.10
88 Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes. Traffic 2003 1.08
89 Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol 2007 1.08
90 Toward structural elucidation of the gamma-secretase complex. Structure 2009 1.07
91 Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem 2003 1.06
92 Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation. J Biol Chem 2002 1.06
93 Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proc Natl Acad Sci U S A 2008 1.06
94 Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J Neurochem 2007 1.05
95 The ups and downs of Abeta. Nat Med 2006 1.04
96 Response to: Pardossi-Piquard et al., "Presenilin-Dependent Transcriptional Control of the Abeta-Degrading Enzyme Neprilysin by Intracellular Domains of betaAPP and APLP." Neuron 46, 541-554. Neuron 2007 1.03
97 Effects of membrane lipids on the activity and processivity of purified γ-secretase. Biochemistry 2012 1.03
98 Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One 2009 1.03
99 Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol 2011 1.03
100 Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation. Mol Neurodegener 2011 1.02
101 Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord 2011 1.01
102 Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 2009 1.01
103 Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype. J Neurochem 2009 1.01
104 Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry 2014 1.00
105 Biochemistry. Intramembrane proteases--mixing oil and water. Science 2002 0.99
106 Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis 2009 0.98
107 Systematic evaluation of candidate ligands regulating ectodomain shedding of amyloid precursor protein. Biochemistry 2013 0.95
108 Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci Lett 2004 0.95
109 Structural biology: enzyme target to latch on to. Nature 2006 0.92
110 Proteolysis of chimeric beta-amyloid precursor proteins containing the Notch transmembrane domain yields amyloid beta-like peptides. J Biol Chem 2002 0.92
111 Protofibrils of amyloid beta-protein inhibit specific K+ currents in neocortical cultures. Neurobiol Dis 2003 0.91
112 HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J Immunol 2009 0.90
113 Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. Neurobiol Aging 2011 0.90
114 beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. FEBS J 2010 0.89
115 Pancortins interact with amyloid precursor protein and modulate cortical cell migration. Development 2012 0.89
116 Aph-1 associates directly with full-length and C-terminal fragments of gamma-secretase substrates. J Biol Chem 2010 0.88
117 How do Soluble Oligomers of Amyloid beta-protein Impair Hippocampal Synaptic Plasticity? Front Cell Neurosci 2010 0.87
118 A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma. Bull Math Biol 2002 0.86
119 Amyloid-lowering isocoumarins are not direct inhibitors of gamma-secretase. Nat Cell Biol 2002 0.86
120 gamma-secretase processing of APLP1 leads to the production of a p3-like peptide that does not aggregate and is not toxic to neurons. Brain Res 2009 0.86
121 Impaired glutamate recycling and GluN2B-mediated neuronal calcium overload in mice lacking TGF-β1 in the CNS. Glia 2013 0.85
122 Α-synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson's disease. Brain Pathol 2011 0.84
123 Presenilin-1-mediated retention of APP derivatives in early biosynthetic compartments. Traffic 2006 0.83
124 A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. Int J Geriatr Psychiatry 2009 0.83
125 Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012 0.83
126 Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology 2008 0.82
127 Plasma beta-amyloid level, cognitive reserve, and cognitive decline. JAMA 2011 0.82
128 Evidence that alpha-synuclein does not inhibit phospholipase D. Biochemistry 2009 0.81
129 Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study. Alzheimer Dis Assoc Disord 2012 0.81
130 Purification of α-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry 2014 0.81
131 Genetic deletion of the GATA1-regulated protein α-synuclein reduces oxidative stress and nitric oxide synthase levels in mature erythrocytes. Am J Hematol 2014 0.80
132 Pen-2 is essential for γ-secretase complex stability and trafficking but partially dispensable for endoproteolysis. Biochemistry 2014 0.78
133 Functional analysis and purification of a Pen-2 fusion protein for γ-secretase structural studies. J Neurochem 2014 0.76
134 Giving Alzheimer's the old one-two. Cell 2010 0.75
135 By the way, doctor. Is there a brain scan that can specifically diagnose Alzheimer's disease? Harv Health Lett 2005 0.75